| Symbol | EQ |
|---|---|
| Name | EQUILLIUM, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2223 AVENIDA DE LA PLAYA,SUITE 105, LA JOLLA, California, 92037, United States |
| Telephone | +1 858 240-1200 |
| Fax | — |
| — | |
| Website | https://www.equilliumbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001746466 |
| Description | Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Equillium, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0001716774-26-000015 <b>Size:</b> 8 KB
Read moreEquillium - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreEquillium - Equillium to Participate inOppenheimer’s 2026 Innovation on the Island Event
Read moreEquillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
Read moreNew Form EFFECT - Equillium, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 9999999995-26-001220 <b>Size:</b> 1 KB
Read moreNew Form ARS - Equillium, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-156107 <b>Size:</b> 3 MB
Read moreNew Form DEFA14A - Equillium, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-156100 <b>Size:</b> 321 KB
Read moreNew Form DEF 14A - Equillium, Inc. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-156092 <b>Size:</b> 8 MB
Read moreEquillium - Equillium Announces Poster Presentations atIMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
Read more